<DOC>
	<DOCNO>NCT01572649</DOCNO>
	<brief_summary>Primary Objective : - To investigate effect two single subcutaneous lixisenatide dos ( 5 10 µg ) compare placebo reduce postprandial glucose ( PPG ) type 2 diabetic paediatric population ( 10-17 year old ) adults controls Secondary Objectives : - To evaluate paediatric adult population : - blood level lixisenatide ( pharmacokinetic ) parameter plasma single subcutaneous ascend dos - maximum post-prandial glucose excursion , change insulin , C-peptide glucagon plasma concentration follow standardize breakfast - safety tolerability .</brief_summary>
	<brief_title>Evaluation Blood Levels Drug ( Lixisenatide ) , Plasma Glucose Levels Safety Paediatric Adult Patients With Type 2 Diabetes</brief_title>
	<detailed_description>The duration study patient plan 4 7 week include screening period ( 25 30 day ) , 3 treatment period 1-7 day apart , period last one day ( Day 1 ) end-of-study visit 1 7 day last dose administration .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion criterion : Male female patient type 2 diabetes mellitus , define WHO ( fast plasma glucose ≥ 7 mmol/L ( 126mg/dL ) 2 hour postprandial plasma glucose ≥ 11.1 mmol/L ( 200 mg/dL ) ) , diagnose least 1 year ( adult ) least 3 month paediatric population time screen visit , without metformin ( stable dose ± 10 % least 4 week prior randomization ) HbA1c ≥ 7 % ≤ 10 % screening Age eligibility paediatric population : ≥ 10 year &lt; 18 year least 3 patient 15 year 3 patient age 16 18 year ; Age eligibility adult : ≥ 18 ≤ 65 year For paediatric population : body weight &gt; 50kg , BMI &gt; 85th percentile age gender BMI ≤ 50 kg/m² For adult : BMI &gt; 25 kg/m2 ≤ 37 kg/m2 Exclusion criterion : If female , pregnancy ( define positive serum pregnancy test ) , breastfeed Diabetes type 2 diabetes Positive test insulinoma associate protein ( IA2 ) glutamic acid decarboxylase ( GAD ) autoantibody Use oral injectable antidiabetic hypoglycemic agent metformin ( e.g. , alpha glucosidase inhibitor , exenatide , DPPIV inhibitor , insulin etc . ) within 3 month prior time screen Allergic reaction GLP1 agonist past ( e.g . exenatide , liraglutide ) metacresol History unexplained pancreatitis , chronic pancreatitis , pancreatectomy , stomach/gastric surgery , inflammatory bowel disease Personal family history medullary thyroid cancer ( MTC ) genetic condition predispose MTC ( e.g. , multiple endocrine neoplasia syndrome ) The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>